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Purpose: To assess visual and anatomical outcomes following the surgical removal of subfo-
veal choroidal neovascular membranes (CNVMs) in older patients without clinical evidence 
of diffuse disease of the retinal pigment epithelium (RPE).
Methods: We retrospectively reviewed records of consecutive patients aged 50 years or 
older who underwent surgical removal of subfoveal CNVMs. Patients with clinical evidence 
for age-related macular degeneration (AMD) (5 small drusen), angioid streaks, and myopic 
degeneration were excluded.
Results: Twenty-two patients (8 women) ranged in age from 50 to 85 years (median, 
67 years). All membranes were 100% classic, with a mean size of 2.5 MPS disc areas 
(range, 1 to 6.5). Best postoperative visual acuity (VA), measured a median 12.5 weeks 
after surgery, improved (3 Snellen lines) in 10 eyes (45%) and worsened in 0 eyes, 
with 8 eyes (36%) achieving 20/50 or better. Over a mean follow-up of 37 months (range, 
6 to 114 months), CNVM recurrence was seen in 13 eyes (59%), causing loss of VA from 
best postoperative levels in 5 eyes (23%). On final follow-up, 4 eyes (18%) retained acuity 
of 20/50 or better, 12 eyes (55%) had disciform scarring, and 5 eyes (23%) had geographic 
atrophy. Improvement in best postoperative VA occurred in a higher percentage of eyes 
with focal (58%) compared with idiopathic (30%) disease, but this trend was not statisti-
cally significant (p = 0.23, Fisher’s exact test).
Conclusions: Surgical removal of subfoveal CNVMs may result in substantial visual improve-
ment in older patients without other clinical evidence for AMD, particularly in eyes with focal 
diseases of the RPE-Bruch’s membrane complex.
Keywords: choroidal neovascularization, idiopathic choroidal neovascular membrane, presumed 
ocular histoplasmosis syndrome, submacular surgery
Introduction
Choroidal neovascularization remains a major cause of central vision loss in adults. 
In the 1980s, laser photocoagulation was the only proven treatment for choroidal 
neovascular membranes (CNVMs). However, laser photocoagulation of subfoveal 
CNVMs damages the overlying neurosensory retina, resulting in immediate loss 
of visual acuity (MPSG 1991). Although immediate loss of visual acuity associ-
ated with verteporﬁ  n photodynamic therapy (PDT) is uncommon, this treatment 
is generally disappointing given that few treated eyes experience substantial 
improvement in visual acuity (TARMDPTSG 1999, 2001; Rosenfeld et al 2004). 
More recently, nonselective anti-vascular endothelial growth factor (VEGF) 
therapy with intravitreal ranibizumab and bevacizumab has been demonstrated to 
result in substantial visual improvement in a signiﬁ  cant subset of treated eyes with 
exudative age-related macular degeneration (AMD) (Rosenfeld et al 2005; Avery 
et al 2006; Brown et al 2006; Spaide et al 2006). Given these results, anti-VEGF Clinical Ophthalmology 2007:1(2) 158
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therapy has rapidly become the standard of care for 
sub-foveal CNVM in AMD and other conditions.
In the early 1990s, submacular surgery was pioneered as 
a treatment with the potential to markedly improve visual 
acuity in eyes with subfoveal CNVMs (Thomas and Kaplan 
1991). Surgical results in various series have conﬁ  rmed that 
signiﬁ  cant improvements in visual acuity can be attained 
with submacular surgery in eyes with presumed ocular his-
toplasmosis syndrome (POHS) and other focal disorders of 
the retinal pigment epithelium-Bruch’s membrane complex 
(Berger and Kaplan 1992; Thomas et al 1992, 1994; Berger 
et al 1997; Holekamp et al 1997; Sears et al 1999; Uemura 
and Thomas 2000). However, the Submacular Surgery Trials 
showed that surgical removal of CNVMs did not result in 
visual beneﬁ  t compared with laser photocoagulation or natu-
ral history in eyes with subfoveal membranes complicating 
AMD (SSTPSI 2000; SSTRG 2004a). Other series have 
similarly shown that signiﬁ  cant visual improvement follow-
ing submacular surgery is rare in eyes with AMD (Berger 
and Kaplan 1992; Thomas et al 1992, 1994; Ormerod et al 
1994; Roth et al 1997).
The Submacular Surgery Group H trial evaluated patients 
with subfoveal CNVMs which were idiopathic or related 
to POHS. This study did not ﬁ  nd a large beneﬁ  t to surgery 
compared to observation over a 24-month period for the 
overall study group. However, patients with preoperative 
visual acuity worse than 20/100 had the largest beneﬁ  t. In 
addition, subgroup analysis found that surgery appeared 
to be more beneﬁ  cial for patients older than age 45 years 
(SSTRG 2004b).
Although anti-VEGF therapy appears very promising 
for CNVM in all clinical contexts, its use has been studied 
extensively only in patients with AMD. Furthermore, 
a substantial percentage of patients treated with effective 
anti-VEGF agents do not respond with signiﬁ  cant improve-
ment in visual acuity. Based on the surprising suggestion 
from the Submacular Surgery Group H study that increased 
age may be a positive prognostic factor for submacular 
surgery in non-AMD eyes, we were interested in evaluating 
our experience with such patients. The purpose of this study 
was to assess long-term visual and anatomical outcomes 
following the surgical removal of CNVMs in older patients 
without separate clinical evidence of AMD, angioid streaks, 
or myopic degeneration.
Patients and methods
We retrospectively reviewed records of 31 consecutive 
patients aged 50 years or older who underwent surgical 
removal of subfoveal CNVMs by one surgeon (MWJ) 
between June 1994 and July 2001. Patients with evidence of 
diffuse retinal pigment epithelium (RPE) disease, including 
AMD, myopic degeneration, and angioid streaks, were 
excluded. In this study, the presence in either eye of greater 
than 5 small drusen or geographic atrophy of the RPE was 
considered diagnostic of AMD. Of the 31 eyes, 3 eyes with 
AMD, 2 eyes with myopic degeneration, 1 eye with angioid 
streaks, and 1 eye with coexisting diabetic macular edema 
were excluded. Additionally, 2 eyes were excluded because 
postoperative follow-up was less than 6 months. The study 
group consisted of 22 eyes of 22 patients. Diagnoses 
included idiopathic CNVMs (10 eyes), presumed ocular 
histoplasmosis (7 eyes), juxtapapillary CNVMs (2 eyes), 
birdshot chorioretinopathy (1 eye), idiopathic central 
serous chorioretinopathy (1 eye), and multifocal choroiditis 
(1 eye). No eyes had features suggestive of polypoidal 
choroidal vasculopathy.
Comprehensive ophthalmic examination including 
visual acuity, anterior segment biomicroscopy, intraocular 
pressure, and fundus examination, was performed preopera-
tively and postoperatively. Visual acuity was obtained in a 
nonstandardized fashion using Snellen charts with manifest 
refraction or with spectacle correction and pinhole. Visual 
acuities worse than 20/400 were classiﬁ  ed retrospectively as 
either 5/200 or 2/200. Fundus photography and ﬂ  uorescein 
angiography were performed on all patients. Review of 
medical records and photographic studies was performed 
after approval from the Institutional Review Board (IRB) 
of our institution.
Detailed informed consent was obtained prior to sur-
gical intervention. Pars plana vitrectomy was performed 
with peeling of the posterior cortical vitreous. A small reti-
notomy was made with a retinal perforator. Balanced Salt 
Solution (BSS, Alcon Laboratories, Fort Worth, TX) was 
used to elevate the retina from the surface of the CNVM. 
Subretinal forceps were placed through the retinotomy and 
used to gently separate and remove the neovascular com-
plex. Neither tissue plasminogen activator nor endolaser 
photocoagulation were employed. Elevation of the infusion 
pressure was used to achieve hemostasis. A partial (approxi-
mately 50%) ﬂ  uid-air exchange was performed and patients 
were instructed to maintain face-down positioning for the 
remainder of the day. Repeat surgical removal was gener-
ally offered to patients who had substantial visual recovery 
following the initial surgery and subsequently developed 
a recurrent subfoveal CNVM with vision loss. During 
repeat surgery, previous sclerotomy sites were avoided Clinical Ophthalmology 2007:1(2) 159
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and the location of the access retinotomy was chosen with 
no consideration of the intial retinotomy site (which was 
typically invisible).
Primary outcome measures were best postoperative visual 
acuity, ﬁ  nal visual acuity, and anatomic status of the macula 
at the ﬁ  nal follow-up examination. Other outcomes evalu-
ated included recurrence of neovascularization, time between 
surgery and recurrence, and the occurrence of surgical com-
plications.
Patients with focal diseases of the RPE-Bruch’s mem-
brane complex were compared with patients with idio-
pathic disease. The Student’s t-test was used to compare 
the age of the two groups. The Fisher’s exact test was 
used to compare the percentage of patients achieving best 
postoperative visual acuity of 20/50 or better as well as 
20/100 or better, and the percentage of patients gaining 3 
or more lines of visual acuity. The log-rank test was used 
to compare the rate of recurrence and the time to recurrence 
between the two groups.
Selected case reports
Case 4
A 59-year-old man with presumed ocular histoplasmosis 
syndrome had a history of extrafoveal CNVM in the left 
eye treated twice with laser photocoagulation. Following 
the second treatment, he developed increased exudation 
and extension of the membrane into the foveal center 
(Figure 1A, B), with decline in visual acuity to 20/200. 
He underwent pars plana vitrectomy with membrane 
removal and partial ﬂ  uid-air exchange. The membrane 
readily separated from the RPE, but was ﬁ  rmly adherent to 
the laser scar. Following complete removal, the subfoveal 
RPE appeared to be intact. On ﬁ  nal follow-up 36 months 
postoperatively, the visual acuity in the left eye was 20/20, 
Figure 1 Case 4. Preoperative fundus photograph (A) and ﬂ  uorescein angiogram (B) of the left eye demonstrating recurrent subfoveal choroidal neovascularization following 
laser photocoagulation of an extrafoveal CNVM. (C) Three years postoperatively, the visual acuity is 20/20.
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and clinical examination revealed no signs of recurrent 
CNVM (Figure 1C).
Case 7
A 74-year-old woman with history of presumed ocular his-
toplasmosis syndrome developed a large CNVM emanating 
from an atrophic choroidal scar superior to the fovea in the 
right eye (Figure 2A, B). Visual acuity declined to 2/200. She 
underwent uncomplicated pars plana vitrectomy with CNVM 
removal. One week postoperatively, she had an area of RPE 
loss in the macular center (Figure 2C). Best postoperative 
visual acuity was 20/400 and ﬁ  nal visual acuity 6.5 months 
after surgery was 5/200.
Case 14
A 65-year-old man with an idiopathic subfoveal CNVM 
(Figure 3A, B) in the left eye was referred for surgery after 
he had been followed for 7 months with growth of the 
CNVM, increased exudation, and decline of best-corrected 
visual acuity to 20/200. He underwent uncomplicated pars 
plana vitrectomy with membrane removal. Three days 
postoperatively, the macular RPE appeared to remain 
intact (Figure 3C). Visual acuity improved to 20/25 
one month following surgery. He developed a recurrent 
subfoveal CNVM 7 weeks postoperatively, for which he 
sought external beam irradiation elsewhere (Figure 3D). 
On ﬁ  nal follow-up 114 months postoperatively, there was 
disciform scarring in the left macula with visual acuity 
of 20/200.
Results
Twenty-two patients (8 women, 14 men) ranged in age from 
50 to 85 years (median, 67 years). Follow-up ranged from 
6 to 90 months (mean, 35 months). Seventeen patients (77%) 
had follow-up greater than 1 year (Table). Six eyes (27%) 
A
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Figure 2 Case 7. Preoperative fundus photograph (A) and ﬂ  uorescein angiogram (B) of the right eye demonstrating a subfoveal CNVM arising from an atrophic choroidal scar 
due to POHS. (C) Fundus photograph of the right eye 1 week postoperatively shows absence of the retinal pigment epithelium (RPE) in the macular center.Clinical Ophthalmology 2007:1(2) 161
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had a history of laser photocoagulation for a juxtafoveal 
or extrafoveal CNVM prior to surgery and one (5%) had 
received previous verteporﬁ  n PDT. All CNVMs were sub-
foveal and 100% classic, with a mean size of 2.5 MPS disc 
areas (range, 1 to 6.5). Five eyes (23%) were pseudophakic 
and 17 (77%) eyes were phakic preoperatively.
Preoperative visual acuity ranged from 20/80 to 2/200 
(median, 20/200). Best postoperative visual acuity was 
measured a median 12.5 weeks after surgery (range, 1 day 
to 69 months) and ranged from 20/20 to 5/200 (median, 
20/100). When compared with preoperative visual acuity, 
the best postoperative visual acuity improved by 3 or more 
Snellen lines in 10 eyes (45%) and worsened in 0 eyes, with 
8 eyes (36%) achieving 20/50 or better.
Over a mean follow-up of 37 months, CNVM recurrence 
was seen in 13 eyes (59%), causing loss of visual acuity 
(3 or more lines) from best postoperative levels in 5 eyes (23%). 
Mean time to recurrence was 14 weeks after surgery, ranging 
from 1 to 48 weeks. Management of recurrences consisted of 
observation in 7 eyes, laser photocoagulation in 3 eyes, repeat 
surgical removal in 2 eyes, and radiation teletherapy in 1 eye. 
Of note was Patient #1 who had 2 recurrences, each treated 
with repeat pars plana vitrectomy and removal of the CNVM. 
Visual acuity returned to 20/25 following the third surgery. 
A subsequent recurrence in the same eye was treated with 
photodynamic therapy, with ﬁ  nal visual acuity of 20/100.
Operative complications included peripheral retinal 
breaks in 5 eyes (23%), limited suprachoroidal hemorrhage 
in 1 eye (5%), intraoperative foveal break in 1 eye (5%), 
and postoperative vitreous hemorrhage in 1 eye (5%). There 
were no cases of retinal detachment or endophthalmitis in 
this series. Of the 17 phakic eyes in this study, 15 (88%) 
had progression of nuclear sclerosis and 4 (24%) underwent 
cataract surgery during the follow-up period.
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Figure 3 Case 14. Preoperative fundus photograph (A) and ﬂ  uorescein angiogram (B) of the left eye demonstrating an idiopathic subfoveal CNVM. (C) Fundus photograph 
of the left eye demonstrating intact retinal pigment epithelium 3 days after submacular surgery. (D) Fundus photograph 56 months postoperatively demonstrating disciform 
scarring after the patient underwent external beam irradiation for a recurrent CNVM.Clinical Ophthalmology 2007:1(2) 162
Wu et al
Patients with focal disease were signiﬁ  cantly younger than 
patients with idiopathic disease (mean age 63 versus 74 years, 
p = 0.007, Student’s t-test). Improvement in best postoperative 
visual acuity of  3 or more lines occurred in a higher percentage 
of eyes with focal (7/12, 58%) compared with idiopathic 
(3/10, 30%) disease, but this difference was not statistically 
signiﬁ  cant, presumably due to small sample size (p = 0.23, 
Fisher’s exact test) (Figure 4). Likewise, an insigniﬁ  cantly 
higher percentage of eyes with focal (5/12, 42%) compared with 
idiopathic disease (3/10, 30%) achieved a best postoperative 
visual acuity of 20/50 or better. There was no signiﬁ  cant 
difference in CNVM recurrence rate between the focal (50%) 
and idiopathic (70%) groups (p = 0.75, log-rank test).
Discussion
Our results demonstrate that surgical removal of subfoveal 
CNVMs may result in signiﬁ  cant visual improvement in older 
patients without clinical evidence of diffuse RPE disease 
such as AMD. In our series, best postoperative visual acuity 
improved substantially in 45% of eyes, with 36% achieving 
reading visual acuity. Although our study was not controlled, 
the outcomes compare favorably to previously reported series in 
younger patients (Berger and Kaplan 1992; Thomas et al 1992, 
1994; Berger et al 1997; Holekamp et al 1997; Sears et al 1999; 
Uemura and Thomas 2000). This observation suggests that 
taken alone, senescence of RPE cells and Bruch’s membrane 
does not preclude the recovery of photoreceptor function 
after the surgical removal of a subfoveal CNVM. Previous 
reports suggest that patients with AMD do not experience 
substantial visual improvement following surgical removal of 
CNVMs, with 0%–9% achieving reading visual acuity at any 
postoperative time point (Thomas et al 1992, 1994; Ormerod 
et al 1994; Roth et al 1997). A pilot study for the Submacular 
Surgery Trials reported results in patients with post-laser 
recurrent CNVMs secondary to AMD. Of the 34 surgically 
treated eyes, only one achieved best postoperative visual 
acuity of 20/40 or better. At the 24-month follow-up, none of 
the patients maintained reading visual acuity (SSTPSI 2000). 
Table Demographic and clinical data
No Sex/Age/
Eye
Diagnosis Previous 
therapy
CNVM Size 
(MPS DA)
Preoperative 
VA
Best
postoperative 
VA
Final 
VA
Follow-up 
(Mos)
Recurrence 
(time to 
recurrence, wks)
Final 
macular 
status
1 M/50/OS POHS 2 20/200 20/25 20/100 45 Yes (10) CNVM
2 F/56/OS POHS 6.5 5/200 20/200 20/200 13 No RPE
Mottling
3 F/56/OS POHS 1.5 20/200 20/30 20/30 17 Yes (1) RPE
Mottling
4 M/59/OS POHS Laser 3.5 20/200 20/20 20/20 36 No RPE
Mottling
5 M/60/OD POHS 2.5 20/80 20/100 20/100 6 Yes (4) Disciform
6 F/61/OS POHS Laser 2 20/100 20/100 20/100 10.5 No Atrophy
7 F/74/OS POHS 4 2/200 20/400 5/200 6.5 No Atrophy
8 F/56/OD Birdshot 4 20/300 20/30 20/50 90 Yes (48) Disciform
9 F/61/OD CSR 1.5 20/300 20/200 5/200 60 Yes (8) Disciform
10 M/67/OD MFC Laser 1 20/200 20/40 20/400 31 No Atrophy
11 M/67/OS Juxtapapillary 3 20/200 20/60 20/60 17 No RPE
Mottling
12 F/85/OD Juxtapapillary Laser 1.5 20/200 20/300 20/400 26.5 Yes (26) Disciform
13 M/60/OD Idiopathic 1 20/200 20/300 2/200 25 Yes (2.5) Disciform
14 M/65/OS Idiopathic 2.5 20/200 20/25 20/200 114 Yes (7) Disciform
I5 M/70/OD Idiopathic 1 20/100 20/200 20/400 76 Yes (14) Disciform
16 M/73/OD Idiopathic Laser 1.5 20/200 20/30 20/30 54 No RPE
Mottling
17 M/74/OS Idiopathic PDT (1) 3 5/200 20/400 5/200 24 No Atrophy
18 M/75/OD Idiopathic 4 20/300 20/25 20/400 28.5 Yes (36) Disciform
19 M/76/OS Idiopathic 2 5/200 20/400 20/400 7.5 Yes (1.5) CNVM
20 F/78/OD Idiopathic 3 2/200 20/400 20/400 69 No Atrophy
21 M/83/OD Idiopathic 1.5 2/200 5/200 2/200 6.5 Yes (12) Disciform
22 M/83/OD Idiopathic Laser 3 20/300 20/100 20/200 56.5 Yes (16) Disciform
Abbreviations: VA, visual acuity; POHS, presumed ocular histoplasmosis; CSR, central serous retinopathy; MFC, multifocal choroiditis; MPS DA, size of standard optic disc 
(1.77 mm2) adopted by the Macular Photocoagulation Study Group; PDT, photodynamic therapy; CNVM, choroidal neovascular membrane; RPE, retinal pigment epithelium.Clinical Ophthalmology 2007:1(2) 163
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Similarly, of the 220 surgically treated eyes in the Submacular 
Surgery Group N trial, only one achieved a best postoperative 
visual acuity of 20/40 or better (SSTRG 2004a).
In contrast to patients with AMD, signiﬁ  cant improve-
ments in visual acuity can be attained with submacu-
lar surgery in POHS and other focal disorders of the 
RPE-Bruch’s membrane complex (Berger and Kaplan 
1992; Thomas et al 1992, 1994; Berger et al 1997). Various 
factors may contribute to the difference in outcomes between 
AMD and focal disorders of the RPE, including underlying 
disease process, growth pattern of the neovascular complex, 
and patient age. CNVMs in focal diseases arise from focal 
dehiscences in an otherwise healthy RPE-Bruch’s mem-
brane complex. In contrast, neovascular AMD develops in 
the setting of widespread dysfunction of the RPE-Bruch’s 
membrane complex. Histological studies (Gass 1994) have 
shown that CNVMs in these two disease categories differ 
with respect to their location relative to the RPE. In AMD, 
CNVMs are typically located beneath and inseparable from 
the RPE layer, which results in extensive removal of RPE 
during surgical extraction of the CNVM. Loss of RPE 
leads to postoperative atrophy of the choriocapillaris and 
photoreceptors, severely compromising visual outcomes. 
In POHS and other focal inﬂ  ammatory conditions, CNVMs 
are located anterior to and separable from the RPE and may 
therefore be removed without signiﬁ  cant alteration of the 
underlying RPE layer.
Animal models have been used to examine the consequences 
of RPE removal. Valentino and co-authors (Valentino et al 
1995) and Del Priore and co-authors (1995) studied RPE 
repopulation after submacular surgery. These investigators 
found that the treated (denuded) area can be repopulated 
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Figure 4 Best postoperative visual acuity in eyes with focal diseases of the RPE compared to eyes with idiopathic CNVM (p = 0.23). Error bars represent 1 standard error.Clinical Ophthalmology 2007:1(2) 164
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by RPE cell migration and proliferation as early as 1 week 
after surgery. Regrowth of the RPE was only observed when 
Bruch’s membrane was intact. Del Priore and co-authors 
(1996) used mitomycin-C for pharmacologic inhibition of 
RPE healing followed by RPE debridement in porcine eyes. 
They found that absence of the RPE led to atrophy of the 
choriocapillaris by 1 week after surgery. These ﬁ  ndings may 
be important in explaining the poor surgical outcomes in 
eyes with AMD compared with eyes with focal RPE dis-
eases. In eyes with AMD, larger amounts of the RPE may 
be removed during submacular surgery, senescent and dis-
eased RPE may have less ability to regenerate, and the RPE 
may be unable to repopulate diseased Bruch’s membrane. 
In addition, choroidal hypoperfusion may further impair 
the physiologic mechanisms required for visual recovery 
(Thach et al 1996).
Experimental evidence suggests that age is an indepen-
dent risk factor for severity of CNVM in a mouse model. 
Espinosa-Heidmann and co-authors (2002) found that older 
age was associated with CNVMs with larger surface area, 
greater vascularity and greater cellularity. However, the 
older age of our patients did not appear to have a signiﬁ  cant 
adverse impact on visual and anatomic outcomes, as these 
outcomes were similar to those of other studies in patients 
with POHS and other focal RPE diseases (Berger and Kaplan 
1992; Thomas et al 1992, 1994; Berger et al 1997; Holekamp 
et al 1997; Sears et al 1999; Uemura and Thomas 2000).
Other published series report a gain of 3 or more lines in 
34%–40% of surgically treated eyes, with 16%–35% achiev-
ing reading visual acuity (Berger and Kaplan 1992; Thomas 
et al 1992, 1994; Berger et al 1997; Holekamp et al 1997). 
Similar results have also been reported in pediatric patients, 
with 25%–43% achieving reading visual acuity (Sears 
et al 1999; Uemura and Thomas 2000). In the Submacular 
Surgery Group H trial (SSTRG 2004b), 18% of surgically 
treated patients versus 13% of patients in the observation 
group had visual acuity better than 20/40 at 36 months. 
Interestingly, older age (greater than 45 years) was found 
to be a potential positive predictor of visual acuity outcome 
on subgroup analysis.
In our series, there was a strong trend toward better 
outcomes in eyes with focal disorders of the RPE-Bruch’s 
membrane complex, compared to those with idiopathic dis-
ease. Among patients with focal diseases, best postoperative 
visual acuity improved by 3 or more Snellen lines in 58% 
compared with 30% of eyes with idiopathic disease. In part 
because of the high recurrence rate (70%), ﬁ  nal outcomes 
in eyes with idiopathic disease were disappointing, with 
only 10% maintaining reading vision on ﬁ  nal follow-up. 
One explanation for this outcome is that idiopathic CNVMs 
may represent a sub-clinical form of AMD, where changes 
in the RPE-Bruch’s membrane complex are not yet clinically 
detectable. However, the initial postoperative recovery of 
reading vision in 30% of patients with idiopathic CNVMs 
suggests that submacular surgery may still have a role in this 
group of patients.
Subfoveal choroidal neovascularization typically 
has devastating effects on the central vision. Although 
anti-VEGF agents appear promising for the treatment of 
CNVMs, a large percentage of treated patients do not expe-
rience a signiﬁ  cant improvement in vision. The possibility 
of postoperative recovery of reading vision in a signiﬁ  cant 
percentage of eyes suggests that submacular surgery should 
still be considered in select patients. We believe that sub-
macular surgery is a reasonable treatment alternative for 
patients with subfoveal CNVMs due to focal disorders 
whose visual acuity is 20/100 or worse despite treatment 
with anti-VEGF agents.
Most of the patients in our series were managed before 
PDT and anti-angiogenic therapies were available. In the 
future, treatment of subfoveal CNVMs associated with idio-
pathic and focal disease will likely involve a multifaceted 
approach, combining pharmacologic therapies with surgery 
in select cases. We are hopeful that the use of effective 
anti-angiogenic drugs for postoperative recurrent CNVMs 
will increase both the magnitude and stability of the visual 
improvement associated with submacular surgery.
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